Skip to content
2000
Volume 26, Issue 28
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Cytomegalovirus is the classic opportunistic infection after solid organ transplantation. This review will discuss updates and future directions in the diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients. Antiviral prophylaxis and pre-emptive therapy are the mainstays of CMV prevention, but they should not be mutually exclusive and each strategy should be considered depending on a specific situation. The lack of a widely applicable viral load threshold for diagnosis and preemptive therapy is emphasized as a major factor that should pave the way for an individualized approach to prevention. Valganciclovir and intravenous ganciclovir remain as drugs of choice for CMV management, and strategies for managing drug-resistant CMV infection are enumerated. There is increasing use of CMV-specific cell-mediated immune assays to stratify the risk of CMV infection after solid organ transplantation, and their potential role in optimizing CMV prevention and treatment efforts is discussed.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612826666200531152901
2020-08-01
2025-06-01
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612826666200531152901
Loading

  • Article Type:
    Review Article
Keyword(s): cidofovir; Cytomegalovirus; foscarnet; ganciclovir; transplantation; valganciclovir
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test